Atara Biotherapeutics announces completion of enrollment in PINTA 745 phase 2 trial
Atara Biotherapeutics announced it completed enrollment in its blinded, randomized, PINTA 745 Phase 2 clinical trial in End-Stage Renal Disease patients with Protein Energy Wasting. The company expects to report preliminary top-line data by the end of the fourth quarter of 2015. August 31, 2015